Prebiotic Strategy: Cultivating a Resilient Internal Ecosystem

Overview

At INNERSTANDIN, we conceptualise the human gastrointestinal tract not merely as a digestive conduit, but as a densely populated, metabolically active bioreactor whose output dictates systemic physiological resilience. For decades, clinical paradigms focused heavily on probiotic supplementation—introducing exogenous transient microbes into a hostile or overcrowded luminal environment. However, contemporary gastroenterological research published in journals such as The Lancet and Nature Medicine indicates that seeding the gut without cultivating the native architecture is an exercise in futility. True intestinal homeostasis requires a shift toward prebiotic strategy: the precise chemical engineering of the luminal habitat to selectively enrich autochthonous, health-promoting taxa. Prebiotics are non-digestible oligosaccharides, resistant starches, and polyphenol conjugates that bypass upper gastrointestinal enzymatic hydrolysis, arriving intact in the caecum and colon to serve as specific metabolic substrates for keystone genera such as Bifidobacterium and Faecalibacterium.

From a mechanistic standpoint, this dietary intervention initiates a cascade of fermentative events with profound systemic ramifications. When saccharolytic anaerobes metabolise these targeted substrates, they generate short-chain fatty acids (SCFAs)—predominantly acetate, propionate, and butyrate. Butyrate serves as the primary colonocytic energy substrate, preserving mitochondrial function and upregulating the expression of tight-junction proteins like claudin-1, occludin, and zonula occludens-1 (ZO-1). This cellular fortification actively mitigates increased intestinal permeability, colloquially termed 'leaky gut', thereby blocking the translocation of lipopolysaccharides (LPS) from Gram-negative bacteria into the portal circulation and arresting systemic low-grade endotoxemia. Propionate is subsequently transported to the liver, where it exerts inhibitory control over hepatic lipogenesis and modulates cholesterol synthesis, while circulating acetate crosses the blood-brain barrier to influence hypothalamic appetite regulation and central neuroinflammation.

Crucially, the UK population—historically lagging behind recommended dietary fibre intake thresholds established by the Scientific Advisory Committee on Nutrition (SACN)—exhibits a high prevalence of dysbiosis linked to ultra-processed dietary patterns. This macronutrient starvation strips the mucosal layer of its protective glycan structures, forcing resident enterocytes to forage on the host's own colonic mucin glycoproteins. Reversing this physiological erosion demands an evidence-led, systematic deployment of prebiotic compounds—such as inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), and human milk oligosaccharide (HMO) analogues—to competitively starve pathobionts and re-establish microbial richness. By interrogating the molecular crosstalk between diet, microbial enzymatic pathways, and host epigenetics, we move past simplistic nutritional advice into the realm of targeted microbial ecology. Prebiotic strategy is the foundational bedrock upon which a resilient internal ecosystem is constructed, safeguarding metabolic, immunological, and neurological homeostasis at the deepest biological level.

The Biology — How It Works

At the physiological core of prebiotic intervention lies the targeted modulation of the human gastrointestinal landscape, shifting the metabolic output from pathogenic proteolysis to saccharolytic fermentation. When non-digestible carbohydrates—predominantly classified as functional prebiotics such as inulin-type fructans, galacto-oligosaccharides (GOS), and resistant starches—escape enzymatic hydrolysis in the upper gastrointestinal tract, they arrive in the proximal colon structurally intact. Here, they encounter a dense, anaerobic microbial consortium. Landmark studies catalogued in The Lancet and indexed across PubMed demonstrate that these substrates act as selective fuel sources, specifically upregulating the metabolic pathways of beneficial genera such as Bifidobacterium and Faecalibacterium. By preferentially stimulating these taxa, a prebiotic strategy exerts competitive exclusion over pathobionts, effectively starving opportunistic gram-negative bacteria that rely on mucosal amino acid fermentation rather than saccharolytic pathways.

The primary mechanism of action extends far beyond mere population shifting; it is fundamentally metabolic. As targeted microbes ferment these prebiotic matrices, they synthesize short-chain fatty acids (SCFAs)—principally acetate, propionate, and butyrate—via anaerobic glycolysis and the acetyl-CoA or acrylate pathways. Butyrate serves as the primary colonocyte energy substrate, ensuring epithelial mitochondrial respiration, hypoxia-inducible factor (HIF) stabilization, and the upregulation of tight junction proteins including zonula occludens-1 (ZO-1) and occludin. This biochemical reinforcement mitigates intestinal permeability, preventing lipopolysaccharide (LPS) translocation into the portal circulation and arresting systemic low-grade endotoxemia. Concurrently, propionate is transported to the liver where it inhibits hepatic cholesterol synthesis, while peripheral acetate acts as a signaling molecule regulating systemic lipid metabolism and neuro-endocrine pathways via the vagus nerve.

Furthermore, the continuous generation of SCFAs maintains luminal acidic pH, an evolutionary defense mechanism characteristic of a resilient internal ecosystem. This localized acidification suppresses the proliferation of pH-sensitive pathogens, including Clostridioides difficile and enteropathogenic Escherichia coli. At INNERSTANDIN, our interrogation of current molecular data reveals that this pH modulation simultaneously enhances the solubility and subsequent absorption of essential divalent cations, notably calcium and magnesium. Beyond the gut lumen, circulating SCFAs engage with specific G-protein coupled receptors, specifically GPR43 (FFAR2) and GPR41 (FFAR3), expressed on immune cells and vascular endothelium. Through these receptor interactions, prebiotics exert profound immunomodulatory effects, promoting the differentiation of naive T cells into forkhead box P3 (Foxp3+) regulatory T cells (Tregs) and suppressing pro-inflammatory cytokine cascades. This intricate biochemical signaling cascade re-establishes immunological homeostasis, proving that strategic prebiotic administration is not merely a dietary supplement strategy, but a foundational biological intervention capable of steering systemic host physiology through microbial mediation.

Mechanisms at the Cellular Level

At the fundamental cellular interface of the human gastrointestinal tract, prebiotic strategy operates far beyond the simplistic paradigm of merely "feeding good bacteria." When non-digestible oligosaccharides—such as inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS)—survive upper gastrointestinal transit and reach the caecal and colonic crypts, they initiate a cascade of profound molecular and epigenetic events. Commensal saccharolytic taxa, predominantly Bifidobacterium and Lactobacillus species, deploy specialized ATP-binding cassette (ABC) transporters and extracellular glycoside hydrolases to cleave these complex polymers into monosaccharides. Subsequent anaerobic fermentation yields short-chain fatty acids (SCFAs)—principally acetate, propionate, and butyrate—which act as critical signaling molecules governing host cellular homeostasis.

At the colonocyte level, butyrate serves as the primary mitochondrial energy substrate via $\beta$-oxidation, a process that consumes oxygen and maintains a physiological state of hypoxia within the mucosal epithelium. This hypoxia-induced stabilization of hypoxia-inducible factor 1-alpha (HIF-1$\alpha$) is paramount; it directly upregulates the transcription of genes encoding tight junction proteins, including claudin-1, occludin, and zonula occludens-1 (ZO-1). By fortifying the apical junctional complex, prebiotic-derived SCFAs physically restrict paracellular translocation of luminal lipopolysaccharides (LPS) and pro-inflammatory cytokines into the lamina propria, effectively neutralizing systemic low-grade endotoxaemia.

Concurrently, these metabolites engage in sophisticated epigenetic regulation. Butyrate and, to a lesser extent, propionate function as potent endogenous inhibitors of histone deacetylases (HDACs). By suppressing HDAC activity, SCFAs promote hyperacetylation of histone tails at specific promoter regions within immune and epithelial cells. This chromatin relaxation permits enhanced transcription of anti-inflammatory pathways, notably the upregulation of forkhead box P3 (FOXP3) expression in naive T cells, thereby driving the differentiation and proliferation of suppressive regulatory T (Treg) cells.

Furthermore, prebiotic metabolites orchestrate mucosal immunity through G-protein coupled receptor (GPCR) activation. SCFAs bind explicitly to GPR41 (FFAR3), GPR43 (FFAR2), and GPR109A expressed on enteroendocrine cells and immune effectors. GPR43 activation on neutrophils and macrophages dampens nuclear factor kappa B (NF-$\kappa$B) translocation, effectively downregulating the production of interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-$\alpha$), and interleukin-1 beta (IL-1$\beta$). Concurrently, stimulation of enteroendocrine L-cells via GPCR signaling triggers the vesicular exocytosis of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), demonstrating that targeted prebiotic intervention exerts systemic metabolic control originating directly at the mucosal-microbial boundary.

Through these multi-tiered molecular pathways—spanning mitochondrial respiration, epithelial barrier fortification, epigenetic modulation, and GPCR-mediated immunomodulation—strategic prebiotic administration transforms the gut from a passive conduit into an active endocrine and immunological organ. Rigorous clinical investigations indexed in major repositories such as PubMed continue to validate these precise mechanisms, underscoring why modern nutritional science must move past caloric reductionism and focus on high-resolution biochemical interactions within the human microbiome.

Environmental Threats and Biological Disruptors

The human gastrointestinal tract does not exist in isolation; it functions as a dynamic, highly sensitive bioreactor continuously besieged by the biochemical artefacts of industrial civilisation. Modern anthropogenic stressors—ranging from ubiquitous xenobiotics and ultra-processed food additives to chronic psychological stress—exert a profound, destabilising pressure on the autochthonous gut microbiota. At INNERSTANDIN, we recognise that deploying a targeted Prebiotic Strategy is not merely a matter of microbial fortification, but an urgent act of ecological remediation against persistent biological disruptors.

Dietary emulsifiers such as carboxymethylcellulose (CMC) and polysorbate-80, extensively characterised in landmark publications in Nature, act as chemical detergents within the luminal environment. By lowering surface tension, these compounds erode the protective inner mucus layer of the colon. This mucous degradation narrows the spatial segregation between the luminal microbiota and the single-layer host epithelium, inciting low-grade mucosal inflammation and downregulating the production of antimicrobial peptides. Concurrently, the pervasive infiltration of dietary advanced glycation end-products (AGEs) and artificial sweeteners (e.g., saccharin, sucralose) alters microbial carbohydrate metabolism, directly inhibiting beneficial phyla such as Bifidobacterium and Lactobacillus while selecting for opportunistic pathobionts capable of metabolising xenobiotic substrates.

Beyond exogenous chemicals, the modern lifestyle inflicts systemic metabolic tolls that reverberate through the gut-organ axes. Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, systematically elevating systemic cortisol and catecholamines. These stress hormones diffuse across the intestinal mucosa, altering luminal pH, increasing tight-junction permeability (claudin and occludin degradation), and signalling a shift in microbial gene expression toward virulence. Furthermore, the UK population’s reliance on polypharmacy—particularly proton-pump inhibitors (PPIs) and non-steroidal anti-inflammatory drugs (NSAIDs)—fundamentally alters gastric acidity and intestinal mucosal blood flow, precipitating profound dysbiosis characterised by a loss of microbial $\alpha$-diversity.

When microbial diversity collapses under this multi-pronged assault, the functional capacity of the ecosystem plummets. Fermentative capacity shifts away from the production of pleiotropic short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate, toward the generation of noxious putrefactive metabolites such as p-cresol, indole, and hydrogen sulfide. These metabolites compromise mitochondrial respiration in colonocytes and exacerbate systemic systemic endotoxemia via lipopolysaccharide (LPS) translocation.

Mitigating this cascade requires a rigorous, evidence-led approach. Standard dietary interventions are frequently insufficient to reverse deep-seated anthropogenic disruption. Instead, establishing ecosystem resilience demands precise, high-affinity prebiotic administration—such as specifically fractionated inulin, galacto-oligosaccharides (GOS), and human milk oligosaccharides (HMOs)—to selectively nourish resilient keystone taxa. By starving pathobionts and biochemically outcompeting inflammatory species through targeted substrate availability, a robust Prebiotic Strategy fortifies the mucosal barrier, re-establishes immune homeostasis, and re-engineers a resilient internal ecosystem capable of withstanding the relentless onslaught of industrial stressors.

The Cascade: From Exposure to Disease

When dietary fibre paucity and xenobiotic disruption compromise the commensal microbiota, a predictable pathophysiological cascade ensues, transitioning local mucosal perturbations into systemic inflammatory states. As demonstrated in landmark studies published in The Lancet and indexed across PubMed repositories, the primary structural failure manifests within the intestinal epithelial monolayer. Fermentable prebiotic deprivation forces mucin-degrading taxa—most notably Akkermansia muciniphila—to forage upon the host’s endogenous O-linked glycans within the protective mucous layer. This enzymatic erosion compromises the biochemical integrity of the inner colonic mucus barrier, leaving the underlying apical surface vulnerable to luminal antigens.

At the molecular level, the loss of targeted saccharolytic fermentation precipitates a precipitous decline in circulating short-chain fatty acids (SCFAs), predominantly butyrate, propionate, and acetate. Butyrate serves as the mandatory oxidative substrate for colonocytes, fueling mitochondrial β-oxidation and preserving cellular hypoxia, which stabilizes hypoxia-inducible factor 1-alpha (HIF-1α) and upregulates tight junction proteins such as claudins, occludins, and zonula occludens-1 (ZO-1). In the absence of adequate prebiotic substrates, intracellular adenosine triphosphate (ATP) production in the epithelium plummets, inducing cytoskeletal rearrangement and the disassembly of intercellular tight junctions.

This barrier failure initiates paracellular translocation of luminal lipopolysaccharides (LPS)—endotoxins derived from the outer membrane of Gram-negative bacilli—into the lamina propria. Upon crossing the mucosal threshold, LPS engages Toll-like receptor 4 (TLR4) on resident macrophages and dendritic cells, triggering an intracellular signaling cascade via myeloid differentiation primary response 88 (MyD88) and subsequent nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) translocation. The resulting transcriptional activation unleashes a proinflammatory cytokine storm characterized by the systemic upregulation of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP).

Within the UK demographic context, where modern ultra-processed dietary patterns routinely restrict complex plant polysaccharides below the Scientific Advisory Committee on Nutrition (SACN) recommendations, this low-grade metabolic endotoxemia underpins the pathogenesis of modern chronic non-communicable diseases. Systemic dissemination of pro-inflammatory cytokines impairs peripheral insulin receptor signaling via serine phosphorylation of insulin receptor substrate-1 (IRS-1), driving hepatic steatosis and peripheral insulin resistance. Furthermore, the neuro-immunoendocrine interface is chronically disrupted; circulating cytokines cross the blood-brain barrier via fenestrated capillaries in the circumventricular organs, activating microglia and propagating neuroinflammation—a primary driver of cognitive decline and mood disorders frequently documented in British epidemiological cohorts.

Simultaneously, hepatic xenobiotic metabolism and phase II conjugation pathways are impaired due to altered enterohepatic circulation of secondary bile acids. Unfavourable shifts in the Firmicutes-to-Bacteroidetes ratio, driven by prebiotic starvation, alter bile acid deconjugation and farnesoid X receptor (FXR) signaling, exacerbating dyslipidaemia and systemic vascular endothelial dysfunction. Here at INNERSTANDIN, our translational analysis underscores that mitigating this cascading pathology requires a paradigm shift: intercepting disease progression demands targeted nutritional re-engineering to restore microbial diversity and reinforce the structural and metabolic fortifications of the host gastrointestinal ecosystem.

What the Mainstream Narrative Omits

The prevailing commercial wellness narrative surrounding prebiotics operates on an egregiously reductionist paradigm: consume a generic dose of inulin or fructooligosaccharides (FOS), feed the bifidobacteria, and automatically secure metabolic homeostasis. This simplistic linear model fundamentally misinterprets the evolutionary ecology of the human gastrointestinal tract. Published literature in journals such as Cell and Nature Microbiology demonstrates that the human lower intestine is not a static bioreactor awaiting any available carbohydrate, but a highly competitive, biogeographically zoned microbial rainforest governed by thermodynamic and cross-feeding networks. Mainstream discourse consistently omits the crucial variable of substrate specificity and spatial architecture within the mucosal lumen. When blanket doses of highly fermentable, short-chain prebiotics are introduced without regard for regional microbial variations, the result is often rapid, proximal fermentation. This precipitates osmotic imbalances, localized gas accumulation, and systemic low-grade distension—a clinical presentation frequently misdiagnosed as generalized carbohydrate intolerance rather than architectural and kinetic mismatching of the substrate.

Furthermore, commercial protocols routinely ignore the profound implications of microbial glycan-foraging hierarchies. As established by seminal work from the UK’s Quadram Institute and global microbiome consortia, commensal taxa do not consume dietary fibres indiscriminately. They employ complex enzyme systems—such as polysaccharide utilisation loci (PULs)—that demand precise molecular conformations. When the mainstream narrative reduces "prebiotics" to a monolith, it fails to account for inter-individual metabolic plasticity. A substrate that upregulates Faecalibacterium prausnitzii butyrate production in a robust, diverse enterotype may starve or paradoxically suppress the same taxa in an ecologically depleted ecosystem dominated by pathobionts. These pathobionts can rapidly exploit unregulated simple sugars, precipitating dysbiosis rather than amelioration.

At INNERSTANDIN, our analysis of clinical trials indexed on PubMed reveals a critical oversight in translational applications: the systemic immunological cascade resulting from unchecked fermentation kinetics. Rapid fermentation of uniform oligosaccharides alters the local pH and luminal redox state, which in turn modulates mucin dynamics by the host epithelium. If the fermentation front occurs too rapidly in the cecum, the distal colon experiences substrate starvation, forcing proteolytic fermentation by opportunistic microbes. This metabolic shift generates toxic metabolites, including p-cresol and hydrogen sulphide, which compromise tight junction integrity—specifically occludin and zonula occludens-1 (ZO-1)—thereby exacerbating systemic endotoxemia. True prebiotic strategy, therefore, requires a paradigm shift away from high-dose, single-molecule supplementation toward precision-engineered, structurally diverse glycan arrays tailored to individual spatial biogeography and metabolic output.

The UK Context

Within the United Kingdom, the deployment of targeted prebiotic strategies intersects with a distinct epidemiological landscape characterised by low habitual dietary fibre intakes and high prevalence rates of chronic non-communicable inflammatory disorders. Data derived from the National Diet and Nutrition Survey (NDNS) consistently demonstrate that the mean British adult fibre consumption hovers near 20 grams per day—substantially below the 30 grams per day scientific recommendation set by the Scientific Advisory Committee on Nutrition (SACN). This profound fibre deficit starves the indigenous saccharolytic microbiota, primarily Bifidobacterium and Lactobacillus genera, precipitating a structural erosion of the colonic mucus layer and triggering a systemic pro-inflammatory cascade. At INNERSTANDIN, we recognise that restoring metabolic homeostasis requires moving beyond simplistic dietary guidelines to implement precise prebiotic modulation. By engineering dietary inputs with specific substrates such as inulin-type fructans, galacto-oligosaccharides (GOS), and resistant starches, clinicians and researchers can selectively enrich beneficial taxa capable of fermenting these compounds into bioactive short-chain fatty acids (SCFAs)—namely acetate, propionate, and butyrate.

Mechanistically, these microbial metabolites serve as the primary colonocyte energy source while exerting profound epigenetic regulation through the inhibition of histone deacetylases (HDACs). Butyrate, in particular, upregulates the transcription of genes responsible for tight junction proteins like zonula occludens-1 (ZO-1) and occludin, thereby repairing intestinal permeability defects commonly exacerbated by the typical Western diet. Furthermore, British cohort studies published in high-impact journals such as The Lancet and indexed within PubMed highlight the systemic ramifications of this mucosal fortification. Enhanced SCFA signalling via G-protein coupled receptors (GPCR41 and GPCR43) modulates hepatic lipogenesis, dampens systemic low-grade inflammation by suppressing nuclear factor kappa B (NF-$\kappa$B) pathways, and optimizes the gut-brain axis through vagal nerve stimulation and neuroendocrine modulation.

Addressing the UK’s public health crisis demands a paradigm shift towards rigorous, evidence-led prebiotic strategies. By shifting the internal ecosystem from a proteolytic to a saccharolytic fermentative profile, individuals can systematically reverse dysbiosis, fortify the immunological firewall of the gut epithelia, and re-establish host-microbiome symbiosis on a molecular level.

Protective Measures and Recovery Protocols

Contemporary clinical investigation reveals that the human gastrointestinal tract is perpetually subjected to xenobiotic stressors, pharmaceutical interventions, and dietary emulsifiers that induce transient or chronic dysbiosis. At INNERSTANDIN, we recognise that restoring mucosal homeostasis requires more than simple dietary inclusion; it demands precise, targeted restorative protocols grounded in molecular gastroenterology. When the intestinal architecture is compromised—characterised by tight junction degradation, zonulin upregulation, and localized epithelial hypoxia—a strategic recovery framework must be deployed to re-establish microbial diversity and fortify the gut-vascular barrier.

The initial phase of any robust recovery protocol necessitates the mitigation of inflammatory cascades and the selective starvation of proteolytic pathobionts. Clinical trials indexed in PubMed demonstrate that broad-spectrum antibiotic therapies and high-fat, ultra-processed diets precipitate a precipitous decline in mucin-degrading specialists such as Akkermansia muciniphila. To reverse this depletion, therapeutic interventions must leverage highly specific fermentable substrates. Unlike generic dietary fibres, precision prebiotics—specifically fractionated long-chain inulin, human milk oligosaccharides (HMOs), and resistant starches of type 2 and type 4—bypass upper gastrointestinal enzymatic hydrolysis to arrive intact within the caecum and proximal colon. Here, they undergo saccharolytic fermentation by commensal Bifidobacterium and Faecalibacterium taxa, yielding short-chain fatty acids (SCFAs), predominantly butyrate, acetate, and propionate.

At the cellular level, butyrate acts as the primary mitochondrial respiratory fuel for colonocytes, stimulating oxidative phosphorylation and inducing physiological hypoxia. This hypoxia is crucial, as it stabilizes hypoxia-inducible factor 1-alpha (HIF-1alpha), which transcriptionally upregulates genes responsible for tight junction integrity, including claudin-1, occludin, and zo-1. Concurrently, luminal propionate translocates via the portal circulation to the liver, where it exerts systemic immunomodulatory effects, suppressing hepatic cholesterol synthesis and dampening systemic low-grade inflammation. Furthermore, the localized acidification of the luminal pH via SCFA production creates a hostile environment for pH-sensitive enteropathogens, including strains of Escherichia coli and Salmonella enterica.

To optimize recovery kinetics, clinical protocols must also account for inter-individual variations in baseline microbial enterotypes. In UK clinical cohorts, high-resolution metagenomic sequencing frequently reveals profound reductions in species richness following pharmaceutical exposure. Consequently, escalation protocols must begin with low-dose, low-viscosity prebiotics to prevent osmotic distress and gas-mediated distension, progressively titrating upwards as the saccharolytic capacity of the microbiome expands. By systematically engineering the luminal environment through evidence-led prebiotic deployment, the internal ecosystem transitions from a state of vulnerability to one of metabolic resilience, safeguarding both mucosal barrier function and systemic immunological competence.

Summary: Key Takeaways

At INNERSTANDIN, our synthesis of contemporary gastroenterological literature—drawing from seminal studies indexed in PubMed and population health analyses by UK research councils—confirms that therapeutic modulation of the gastrointestinal microbiota requires a shift from passive dietary fiber intake to precision prebiotic strategies. Mechanistically, administration of fermentable oligosaccharides such as inulin and galacto-oligosaccharides (GOS) bypasses upper gastrointestinal enzymatic hydrolysis, serving as selective substrates for autochthonous taxa including Bifidobacterium and Faecalibacterium prausnitzii. This microbial cross-feeding cascade upregulates the saccharolytic fermentation of non-digestible carbohydrates, culminating in elevated luminal concentrations of short-chain fatty acids (SCFAs), predominantly acetate, propionate, and butyrate.

Systemically, these microbial metabolites transcend the gut-vascular barrier, acting as potent epigenetic modulators via the inhibition of histone deacetylases (HDACs) and the activation of G-protein coupled receptors (GPR41, GPR43, and GPR109A). This biochemical signalling axis orchestrates mucosal immune homeostasis, downregulates systemic pro-inflammatory cytokine expression, and reinforces enterocyte tight junction integrity through the upregulation of mucin gene transcription and zonula occludens-1 expression. Ultimately, deploying targeted prebiotic interventions cultivates a resilient internal ecosystem capable of mitigating chronic low-grade systemic inflammation and optimising metabolic resilience across the host lifespan.